von Willebrand factor: Evidence for variable clearance in vivo according to Y/C1584 phenotype and ABO blood group

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 1, 2008, Pages 97-103

  Davies, J A ^a   Collins, P W ^a   Hathaway, L S ^b   Bowen, Derrick J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

ABO blood group; Factor VIII; Von Willebrand factor; Von Willebrand factor propeptide; Y C1584 polymorphism

Indexed keywords

BLOOD CLOTTING FACTOR 8; CYTOSINE; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD DONOR; BLOOD GROUP A; BLOOD GROUP ABO SYSTEM; BLOOD GROUP O; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ABO BLOOD-GROUP SYSTEM; FACTOR VIII; GENOTYPE; HUMANS; MUTATION, MISSENSE; PHENOTYPE; POLYMORPHISM, GENETIC; VON WILLEBRAND FACTOR;

EID: 37549063970     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02809.x     Document Type: Article

References (22)

1. Jaffe EA, Hoyer LW, Nachman RL. Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci USA 1977; 71: 1906-9.
2. Nachman R, Levin R, Jaffe EA. Synthesis of FVIII antigen by cultured guinea-pig megakaryocytes. J Clin Invest 1977; 60: 914-21.
3. Tuddenham EGD, Cooper DN. The von Willebrand factor and von Willebrand disease. In: Tuddenham EGD, Cooper DN, eds. The Molecular Genetics of Haemostasis and its Inherited Disorders. Oxford Monographs on Medical Genetics, Vol. 25. Oxford: Oxford University Press, 1994: 25.
4. Fay PJ, Kawai Y, Wagner DD, Ginsburg D, Bonthron D, Ohlson-Wilhelm BM, Shavin SI, Abraham GN, Handin RI, Orkin SH, Montgomery RR, Marder VJ. Propolypeptide of von Willebrand factor circulates in blood and is identical to von Willebrand antigen II. Science 1986; 232: 995.
5. Sporn LA, Marder VJ, Wagner DD. Differing polarity of the constitutive and regulated secretory pathways for von Willebrand factor in endothelial cells. J Cell Biol 1989; 108: 1283-9.
6. Wagner DD, Fay PJ, Sporn LA, Sinha S, Lawrence SO, Marder VJ. Divergent Fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci USA 1987; 84: 1955-9.
7. Borchiellini A, Fijnvandraat K, ten Cate JW, Pajkrt D, van Deventer SJ, Pasterkamp G, Meijer-Huizinga F, Zwart-Huinink L, Voorberg J, van Mourik JA. Quantitative analysis of von Willebrand factor propeptide release in vivo: Effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 1996; 88: 2951-8.
8. van Mourik JA, Boertjes R, Huisveld IA, Fijnvandraat K, Pajkrt D, van Genderen JJ, Fijnheer R. Von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation. Blood 1999; 94: 179-85.
9. Brown SA, Eldridge A, Collins PW, Bowen DJ. Increased clearance of von Willebrand factor antigen post-DDAVP in type 1 von Willebrand disease: is it a potential pathogenic process? J Thromb Haemost 2003; 1: 1714-7.
10. van Genderen PJJ, Boertjes RC, van Mourik JA. Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome. Thromb Haemost 1998; 80: 495-8.
11. Haberichter SL, Balistreri M, Christopherson P, Morateck P, Gavazova S, Bellissimo DB, Manco-Johnson MJ, Gill JC, Montgomery RR. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006; 108: 3344-51.
12. Eikenboom JCJ, Castaman G, Kamphuisen PW, Rosendaal FR, Bertina RM. The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor. Thromb Haemost 2002; 87: 252-7.
13. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 1691-5.
14. Davies JA, Collins PW, Hathaway L, Bowen DJ. The effect of von Willebrand factor Y/C1584 on in vivo protein level and function, and interaction with ABO blood group. Blood 2007; 109: 2840-6.
15. O'Brien LA, James PD, Othman M, Berber E, Cameron C, Notley CR, Hegadorn CA, Sutherland JJ, Hough C, Rivard GE, O'Shaunessey D, Lillicrap D, Association of Hemophilia Clinic Directors of Canada Founder. von Willebrand factor haplotype associated with type 1 von Willebrand disease. Blood 2003; 102: 549-57.
16. de Romeuf C, Mazurier C. Comparison between von Willebrand factor (VWF) and VWF antigen II in normal individuals and patients with von Willebrand disease. Thromb Haemost 1998; 80: 37-41.
17. Saenko EL, Yakhyaev AV, Mikhailenko I, Strickland DK, Sarafanov AG. Role of the low density lipoprotein-related receptor in mediation of factor VIII catabolism. J Biol Chem 1999; 274: 37685-92.
18. Nossent Ay, van Marion V, van Tilburg NH, Rosendaal FR, Bertina RM, van Mourik JA, Eikenboom HCJ. von Willebrand factor and its propeptide: The influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost 2006; 4: 2556-62.
19. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-94.
20. Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 2003; 1: 33-40.
21. O'Donnell JS, McKinnon TA, Crawley JT, Lane DA, Laffan MA. Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood 2005; 106: 1988-91.
22. Bowen DJ, Collins PW. An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13. Blood 2004; 103: 941-7.